Soligenix (SNGX) Other Non Operating Income (2013 - 2026)
Soligenix's (SNGX) quarterly Other Non Operating Income came in at -$1516.0 in Q1 2026, down 92.39% YoY from -$19910.1 in Q1 2025, and up 46.15% on a QoQ basis from -$2815.0 in Q3 2025.
Soligenix (SNGX) Other Non Operating Income (2013 - 2026) Analysis & Trends
Soligenix (SNGX) has 9 years of Other Non Operating Income data on file, last reported at -$1516.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 92.39% year-over-year to -$1516.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12376.0 (down 102.02% YoY) and the FY2025 annual result came in at $125.0, down 99.98% from the prior year.
- Other Non Operating Income climbed to -$1516.0 in Q1 2026, from -$2815.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $549789.0 in Q4 2024 to a low of -$108293.0 in Q1 2022.
- A 5-year average of $62972.4 and a median of -$106.5 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income surged 8800.73% — and 2025, when it slumped 589.57%.
- Tracing SNGX's Other Non Operating Income over 5 years: stood at -$4543.0 in 2022, then surged by 8800.73% to $395274.0 in 2023, then jumped by 39.09% to $549789.0 in 2024, then slumped by 100.51% to -$2815.0 in 2025, then jumped by 46.15% to -$1516.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1516.0 (Q1 2026), -$2815.0 (Q3 2025), and -$8045.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58,511.00 |
| Mar 31, 2026 | -1,516.00 |
| Sep 30, 2025 | -2,815.00 |
| Jun 30, 2025 | -8,045.00 |
| Mar 31, 2025 | -788.00 |
| Dec 31, 2024 | 549,789.00 |
| Sep 30, 2024 | 575.00 |
| Jun 30, 2024 | 64,248.00 |
| Mar 31, 2024 | 1,209.00 |
| Dec 31, 2023 | 395,274.00 |
| Sep 30, 2023 | -3,046.00 |
| Jun 30, 2023 | 2,354.00 |
| Mar 31, 2023 | 40,869.00 |
| Dec 31, 2022 | -4,543.00 |
| Sep 30, 2022 | -12,613.00 |
| Jun 30, 2022 | 94,900.00 |
| Mar 31, 2022 | -108,293.00 |
| Dec 31, 2021 | 53,138.00 |
| Sep 30, 2021 | 30,754.00 |
| Jun 30, 2021 | 421,584.00 |